Faculty Opinions recommendation of Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes: Randomized Controlled Trial.

Author(s):  
Richard N Brown
2019 ◽  
Vol 220 (1) ◽  
pp. S36
Author(s):  
Maureen S. Hamel ◽  
Lindsey Kanno ◽  
Phinnara Has ◽  
Michael Beninati ◽  
Dwight J. Rouse ◽  
...  

2020 ◽  
Author(s):  
Yanhui Hao ◽  
Yanting Wu ◽  
Zhirou Chen ◽  
Jianxia Fan ◽  
Lei Chen ◽  
...  

BACKGROUND With the rapid development of eHealth technologies, the convenient exchange of health-related electronic data can promote interactive exchange of information between healthcare providers (HCPs) and patients, making the communication between doctors and patients more coordinated and transparent. The Sino-Canada Healthy Life Trajectories Initiative (SCHeLTI) study is an ongoing randomized controlled trial to evaluate the effectiveness of a multifaceted, community-family-mother-child intervention on childhood overweight and obesity (OWO). A management system to support the SCHeLTI interventions needs to be developed. OBJECTIVE Considering the need for a supporting system to facilitate the implementation of interventions and the exchange of information between HCPs and participants, the SCHeLTI platform was designed and developed with the aim to facilitate the context-specific interventions in the SCHeLTI study. METHODS We tailored the SCHeLTI platform to the specifics of the SCHeLTI study. Multiple professional background experts were involved in the process of building the application, including the participation of personnel with medical professional background, clinical trials coordination and computer science. In the pilot phase, we collected feedback from HCPs and participants in the use process to further optimize the product. RESULTS The SCHeLTI platform includes the interworking and interconnection between the participants' mobile phone and the HCP's computers. A mobile application and a Web based management system were designed. The participant's terminal (the SCHeLTI APP) was successfully implemented and fully integrated into the intervention programme. The computer terminal managed by the research team create an innovative support environment that guides the participants toward healthy lifestyle changes. CONCLUSIONS A technically advanced and web-based management terminal and mobile phone app corresponding to the SCHeLTI needs were developed and used in the SCHeLTI study. CLINICALTRIAL trial registration No. ChiCTR1800017773


Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Pascal Chiari ◽  
Michel Durand ◽  
Olivier Desebbe ◽  
Marc-Olivier Fischer ◽  
Diane Lena-Quintard ◽  
...  

Abstract Background Myocardial damage in patients undergoing cardiac surgery increases both morbidity and mortality. Different protective strategies dealing with either preconditioning or postconditioning or assessing a single aspect of cardioprotection have shown conflicting results. We tested the hypothesis that a multimodal approach would improve cardioprotection and limit myocardial damage following cardiac surgery with cardiopulmonary bypass. Methods This study is a pragmatic multicenter (six French institutions), prospective, randomized, single-blinded, controlled trial. The randomization is stratified by centers. In the study, 210 patients scheduled for aortic valve surgery with or without coronary artery bypass grafting will be assigned to a control or a treatment group (105 patients in each group). In the control group, patients receive total intravenous anesthesia with propofol and liberal intraoperative blood glucose management (initiation of insulin infusion when blood glucose, measured every 60 min, is greater than 180 mg/dl), as a standard of care. The treatment group receives a bundle of care combining five techniques of cardioprotection: (1) remote ischemic preconditioning applied before aortic cross-clamping; (2) maintenance of anesthesia with sevoflurane; (3) tight intraoperative blood glucose management (initiation of insulin infusion when blood glucose, measured every 30 min, is greater than 140 mg/dl); (4) moderate respiratory acidosis (pH 7.30) at the end of cardiopulmonary bypass; and (5) a gentle reperfusion protocol following aortic unclamping. The primary outcome is myocardial damage measured by postoperative 72-h area under the curve of high-sensitivity cardiac troponin I. Discussion The ProCCard study will be the first multicenter randomized controlled trial aiming to assess the role of a bundle of care combining several cardioprotective strategies to reduce myocardial damage in patients undergoing cardiac surgery with cardiopulmonary bypass. Trial registration ClinicalTrials.gov, NCT03230136. Registered on July 26, 2017. Last updated on April 17, 2019.


Sign in / Sign up

Export Citation Format

Share Document